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Major depressive disorder (MDD) is a common complex trait with enormous public health
significance. As part of the Genetic Association Information Network (GAIN) initiative of the US
Foundation for the National Institutes of Health, we conducted a genomewide association study of
435,291 SNPs genotyped in 1,738 MDD cases and 1,802 controls selected to be at low liability for
MDD. Eleven of the top 200 signals localized to a 167 kb region overlapping the gene piccolo
(PCLO, whose protein product localizes to the cytomatrix of the presynaptic active zone and plays
an important role in monoaminergic neurotransmission in the brain) with p-values of 7.7×10−7 for
rs2715148 and 1.2×10−6 for rs2522833. We undertook replication of SNPs in this region in 5
independent samples (6,079 MDD independent cases and 5,893 controls) but no SNP exceeded the
replication significance threshold when all replication samples were analyzed together. However,
there was heterogeneity in the replication samples, and secondary analysis of the original sample
with the sample of greatest similarity yielded p=6.4×10−8 for the non-synonymous SNP
rs2522833 that gives rise to a serine to alanine substitution near a C2 calcium-binding-domain of
the PCLO protein. With the integrated replication effort, we present a specific hypothesis for
further studies.
Keywords
major depressive disorder; genome-wide association; Netherlands Study of Depression and
Anxiety; Netherlands Twin Registry
Introduction
The defining features of major depressive disorder (MDD) are marked and persistent
dysphoria plus additional cognitive signs and symptoms (anhedonia, sleep disturbance,
weight/appetite changes, motor agitation/retardation, anergia, excessive guilt or
worthlessness, poor concentration or indecisiveness, and recurrent thoughts of death or
suicide) (1). MDD is distinct from normal sadness by its persistence (i.e., ≥2 weeks),
additional signs and symptoms, and substantial associated impairment. The definition of
MDD excludes other conditions typified by substantial depressive symptoms (other
psychiatric disorders, drug/alcohol dependence, and somatic diseases). The lifetime
prevalence of MDD is ∼15% (2-4) and is twofold higher in women (5) with a course
typified by recurrence of illness (6). It is associated with considerable morbidity (7-9),
excess mortality from suicide and other causes (10-13), and substantial direct and indirect
costs (14). A WHO study projected MDD to be the second leading cause of disability
worldwide by 2020 (15).
Although there is a considerable corpus of research on the epidemiology and biological
correlates of MDD, little is known for certain about its etiology. An important etiological
clue may be the familial tendency of MDD and its heritability of 31-42% (16). This clue led
to a number of genomewide linkage studies (Supplemental Methods) and studies of >100
theoretical or positional candidate genes. As for the use of these study designs with other
biomedical disorders, their application to MDD has not been as successful as had been
hoped.
It is now clear that genomewide association studies (GWAS) can be a successful tool in the
genetic dissection of complex biomedical disorders (17,18). The goal of this report is to
describe a GWAS for MDD that was systematically designed to remediate a set of
methodological issues common to genetic studies of MDD. Examples of these issues include
small sample sizes, inhomogeneous samples in terms of ancestry and phenotyping,
convenience sampling, and controls that are unaffected but not at low liability for MDD.
Moreover, large-scale replication was integral to our design.
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Methods
This GWAS was one of the six initial Genetic Association Information Network (GAIN)
studies sponsored by the Foundation for the NIH (19). Individual phenotype and genotype
data are available to researchers via application to the dbGaP repository (20). We have
attempted to follow published guidelines for GWAS (21, Box 1).
Subjects
The parent projects that supplied subjects for this GWAS are longitudinal studies, the
Netherlands Study of Depression and Anxiety (NESDA, http://www.nesda.nl) (22) and the
Netherlands Twin Registry (NTR, http://www.tweelingenregister.org) (23). Sampling and
data collection characteristics of the GAIN-MDD study have been described in detail
elsewhere (24).
MDD cases were mainly from NESDA, a longitudinal cohort study designed to be
representative of individuals with depressive and/or anxiety disorders. Recruitment of
participants for NESDA took place from 09/2004-02/2007, and ascertainment was from
outpatient specialist mental health facilities and via primary care screening. Additional cases
were from the population-based cohorts NEMESIS (25), ARIADNE (26), and the NTR.
Regardless of recruitment setting, similar inclusion and exclusion criteria were used to select
MDD cases. Inclusion criteria were a lifetime diagnosis of DSM-IV MDD (1) as diagnosed
via the Composite International Diagnostic Interview psychiatric interview (27), age 18-65
years, and self-reported western European ancestry. Persons who were not fluent in Dutch
and those with a primary diagnosis of schizophrenia or schizoaffective disorder, obsessive
compulsive disorder, bipolar disorder, or severe substance use dependence were excluded
(the etiology of MDD in these subjects may be distinct). The 1,862 cases included in GAIN
were recruited from mental health care organizations (N=785), primary care (N=603), and
community samples (NEMESIS N=218, ARIADNE N=96 and NTR N=160).
Control subjects were mainly from the NTR, which has collected longitudinal data from
twins and their families since 1991 (total cohort of ∼22,000 participants from 5,546
families). The majority of families were recruited when the twins were adolescents or young
adults through city council registrations along with alternative efforts to recruit older twins.
Longitudinal phenotyping includes assessment of depressive symptoms (via multiple
instruments), anxiety, neuroticism, and other personality measures. Inclusion required
availability of both survey data and biological samples, no report of MDD at any
measurement occasion, and low genetic liability for MDD. No report of MDD was
determined by specific queries about medication use or whether the subject had ever sought
treatment for depression symptoms and/or via the CIDI interview. Low genetic liability for
MDD was determined by the use of a factor score derived from longitudinal measures of
neuroticism, anxiety, and depressive symptoms (28) (mean 0, std 0.7); controls were
required never to have scored highly (≥0.65) on this factor score. Finally, controls and their
parents were required to have been born in the Netherlands or western Europe. Only one
control per family was selected. There were N=1,703 controls from the NTR and additional
controls from NESDA (N=133 from general practice, N=24 from ARIADNE). NESDA
controls had no lifetime diagnosis of MDD or an anxiety disorder as assessed by the CIDI
and reported low depressive symptoms at baseline (K-10 score <16 and Inventory of
Depressive Symptoms score <4) (29,30).
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Case-Control Matching
If there were multiple eligible NTR controls in a family, we first matched on sex and age,
and used the highest number of completed questionnaires as an additional criterion. Again,
only one control per family was included.
DNA Sampling
Before the start of the NESDA and NTR biological sample collection, processing, and
storage protocols were harmonized and DNA extraction was conducted concurrently in the
same laboratory. For NESDA, blood sampling for the NESDA participants took place
during the baseline visit (between 0830-0930) and DNA was isolated using the FlexiGene
DNA AGF3000 kit (Qiagen, Valencia, CA, USA) on an AutoGenFlex 3000 workstation
(Autogen, Holliston, MA, USA). For NTR, biological samples were taken in the subject's
home (between 0700-1000) and DNA was extracted using the Puregene DNA isolation kit
(Gentra, Minneapolis, MN, USA) for frozen whole blood samples. DNA concentrations
were determined using the PicoGreen dsDNA Quantitation kit (Invitrogen Corporation,
Carlsbad, CA, USA). All procedures were performed according to the manufacturer's
protocols.
Ethical Issues
The NESDA and NTR studies were approved by the Central Ethics Committee on Research
Involving Human Subjects of the VU University Medical Center, Amsterdam, an
Institutional Review Board certified by the US Office of Human Research Protections (IRB
number IRB-2991 under Federal wide Assurance-3703; IRB/institute codes, NESDA
03-183; NTR 03-180). All subjects provided written informed consent. As part of the GAIN
application process, consent forms were specifically re-reviewed for suitability for the
deposit of de-identified phenotype and genotype data into the controlled-access dbGaP
repository (20). NESDA and NTR subjects were informed of participation in GAIN via
newsletters. Only 22 NESDA respondents refused informed consent for genetic research
(1.7% of all respondents approached).
GWAS Genotyping
Individual genotyping was conducted by Perlegen Sciences (Mountain View, CA, USA)
using a set of four proprietary, high-density oligonucleotide arrays. The SNPs on these
arrays were selected to tag common variation in the HapMap European and Asian panels
using previously described genotype data (31), tagging approach (32), and methodology
(33). At the beginning of GAIN, all HapMap (34) samples were genotyped with the
Perlegen GWAS platform. Independent review of these data by the GAIN analysis group
(19) showed 99.8% agreement with prior HapMap genotypes and the mean maximum r2
between the Perlegen SNPs and HapMap phase II SNPs (31) was 0.89 for single and 0.96
for multi-marker analyses. The genotyping procedures and genotyping calling algorithms are
described in the Supplemental Methods and in prior reports (35,36). Briefly, 40 × 96-well
plates were sent to Perlegen for GWAS genotyping. Genotyping was conducted blind to
case-control status. Cases and controls were randomly allocated to plates and to positions
within plates. Each plate contained DNA samples from 93 Dutch subjects plus 3 quality
control samples. The three quality control samples included: two parents of one control on
that plate (40 complete trios in total); and half the plates contained the same HapMap CEU
sample (used for quality control in all GAIN projects) and half had a randomly-selected
duplicate case sample. The total number of samples was 3,840 (=40 plates × 96 samples per
plate) or 1,860 cases + 1,860 controls + 80 parents + 20 duplicate samples + 20 HapMap
samples.
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Quality Control – Subjects
Of the 3,820 Dutch samples sent to Perlegen (excluding the 20 HapMap internal control
samples), genotypes were delivered for 3,761 samples. Fifty-nine samples did not have
GWAS data: 39 samples with uncertain linkage between genotype and phenotype records, 7
samples with evidence of contamination, 6 samples that failed genotyping, and 7
miscellaneous failures (2 of these were excluded as chrX and chrY genotyping data were
consistent with the presence of XO and XXY sex chromosome status). After further
analysis, 8 subjects were removed for excessive missing genotype data (>25%), 1 case for
high genomewide homozygosity (∼75%), 38 subjects whose genomewide IBS estimates
were consistent with first- or second-degree relationships, and 57 additional subjects whose
ancestry diverged from the remainder of the sample (see Supplemental Methods for details).
After these exclusions (N=104) and removing duplicated and trio quality control sample,
there were 3,540 subjects in the final analysis dataset including 1,738 cases and 1,802
controls. The principal reason for fewer cases than controls was the higher prevalence of
substantial non-European ancestry. The list of subjects in the final analyses dataset is
included as a Supplemental File (“mddC.fam”).
Quality Control – SNPs
The unfiltered dataset obtained from dbGaP contained 599,156 unique SNPs. The Perlegen
genotyping algorithm yielded a quality score for each individual genotype, and a more
stringent quality score cutoff (≥ 10) than that used by Perlegen was applied. The SNP
quality control process is described in detail in the Supplemental Methods. Briefly, to be
included in the final analysis dataset, SNPs were required not to have any of the following
features: gross mapping problem (37), ≥2 genotype disagreements in 40 duplicated samples,
≥2 Mendelian inheritance errors in 38 complete trio samples, minor allele frequency <0.01,
or >0.05 missing genotypes in either cases or controls. A Hardy-Weinberg filter was not
used as lack of fit to Hardy-Weinberg expectations can occur for valid reasons (e.g., a true
association) (38) and given that 95.6% (=51,592/53,994) of SNPs with p<0.00001 from an
exact test of Hardy-Weinberg equilibrium (39) in controls were already flagged for
exclusion. A total of 435,291 SNPs met these criteria and were included in the final analysis
dataset (included as a Supplemental File, “mddC.bim”). Additional quality control checks
are described in the Supplemental Methods). Thirteen controls were genotyped in a different
study using the Illumina 317K platform and, of the 82,636 SNPs common to both platforms,
the genotype agreement was 99.94%.
Single Marker Statistical Analyses
There were three classes of SNPs – those that could be heterozygous in all subjects (chr1-22
and chrX/PAR1), those that were heterozygous in females (non-PAR chrX), and those that
were hemizygous in males (non-PAR chrX and chrY). All SNPs that passed quality control
checks were tested for association with MDD using 1 df Cochran-Armitage trend tests. For
complex traits, it is widely believed that the contributions of individual SNPs to disease risk
are often roughly additive (40) . The Cochran-Armitage trend test can be used to detect such
effects. This test is usually recommended due to its robustness to the violation of the HWE
assumption (41): P-values from females and males for non-PAR chrX were combined using
Fisher's method (42).
Population stratification artifacts were assessed in two ways. As described elsewhere (36),
including principal components as covariates in a logistic regression model can robustly
control stratification effects. To do this, we identified a set of 127,688 SNPs in linkage
equilibrium (43) and used the “smartpca” program in EigenSoft (44) to compute 10 principal
components for each subject that were included as covariates in logistic regression models
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(case/control status ∼ SNPi + PC1 + PC2 + … + PC10). We also used a stratified Cochran-
Mantel-Haenszel test in PLINK (43) as a complementary approach.
For noteworthy associations, there were additional checks to ensure that an association was
not due to experimental bias. These checks included: manual inspection of SNP cluster plots
to ensure reasonable performance of the genotyping calling algorithm; evaluation of
conformation to Hardy-Weinberg equilibrium in controls, cases, and overall (discussed in
the Supplemental Methods); the checks for population stratification described above;
evaluation of plate-specific association results to ensure that the overall association was not
driven by one or a few plates; comparison of control MAFs to the HapMap EUR panel; and
evaluation of the characteristics of a SNP in high linkage disequilibrium (“proxy
association”) as a similar association with such a SNP decreases the chance of some forms
of method artifacts.
Control of False Discoveries
Given the 105-107 statistical comparisons in a GWAS, small p-values are expected by
chance. To control the risk of false discoveries, q-values (45,46) were computed for all p-
values for single-marker tests of association. A q-value is an estimate of the proportion of
false discoveries among all significant markers, or the false discovery rate (FDR) for the
corresponding p-value. The use of q-values is preferable to more traditional multiple testing
controls because q-values provide a better balance between the competing goals of finding
true positives versus controlling false discoveries, allow more similar comparisons across
studies because proportions of false discoveries are much less dependent on the number of
tests conducted and are relatively robust against the effects of correlated tests (45,47-54).
The q-value threshold for declaring significance was 0.10 (i.e., the top 10% of the
significant findings are, on average, allowed to be false discoveries) (50,55). FDR thresholds
<0.10 result in a disproportionate drop in power to detect true effects.
Imputation
We used two imputation approaches, the SNPMStat method of Lin et al. (56) to impute 246
additional SNPs in the PCLO region and Abecasis' MACH (v1) to impute 2,037,829
autosomal SNPs with R2 ≥ 0.5 (a cutoff that removes ∼90% of SNPs with unreliable
imputation results while sacrificing 2-3% of reliably imputed SNPs). Both SNPMStat and
MACH gave similar results in the PCLO region. Imputed genotypes were used in secondary
analyses. The HapMap2 EUR panel (31,34) was used as reference.
Statistical Power
Quanto (57,58) was used to approximate statistical power given the following assumptions:
two-tailed α=1×10−7 (=0.05/500,000), 1,738 cases and 1,802 controls, lifetime morbid risk
of MDD of 0.15, and a log additive genetic model. For statistical power of 0.80 (β=0.20),
the minimum detectable genotypic relative risks are 1.59, 1.40, and 1.35 for minor allele
frequencies of 0.10, 0.25, and 0.40.
Software
PLINK (v1.0) (43), SAS (v9.1.3) (59), R (v2.6.1) (60), HAPSTAT (v3) (61-63), MACH1,
SNPMStat (56), HaploView (64), and JMP (v6) (65) were used for data management,
quality control, statistical analyses, and graphics.
Bioinformatics
All genomic locations are per NCBI Build 35 (66) (UCSC hg17) (67). Pseudo-autosomal
region 1 (PAR1) is assumed to be located on chrX:1-2,692,881 and chrY:1-2,692,881 and
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PAR2 on chrX:154,494,747-154,824,264 and chrY:57,372,174-57,701,691 (68). SNP
annotations were per TAMAL (37) based chiefly on UCSC genome browser files (67),
HapMap (34), and dbSNP (66).
Results
Sample Description
Table 1 presents descriptive data for cases and controls. Controls had a higher proportion of
males and were slightly older (and thus were farther through the period of risk for MDD).
Consistent with known correlates of MDD, cases had a significantly lower educational level,
less often had a partner, were more often smokers, and scored much higher on the NEO-FFI
neuroticism scale.
SNP Description
The analysis SNP set had 435,291 SNPs including 427,049 autosomal SNPs, 7.988 SNPs on
the non-PAR portions of chrX, 239 SNPs on chrXY/PAR1, 15 SNPs on chrY, and 0 SNPs
on PAR2. The median SNP missingness was 0.00339 (inter-quartile range 0.00113-0.0105)
and the median minor allele frequency was 0.2422 (inter-quartile range 0.1375-0.3646) with
similar estimates in cases and controls. The average marker density over the genome was 1
SNP every 7,069 bases (=3,077,088,087 bases / 435,291 SNPs). The median inter-marker
distance was 2,911 bases with interquartile range 966-7,374 bases and a 99th percentile of
50.1 kb.
Single Marker Association Tests
We used the Cochran-Armitage trend test to test for association of the 435,291 SNPs in the
GWAS dataset with case/control status. The estimated lambda (69) was 1.046 (similar p-
value minima and lambdas were obtained using logistic regression with 10 principal
components and using a stratified Cochran-Mantel-Haenszel tests based on identity-by-state
clusters) (43,44). The minimum q-value was 0.28 (i.e., if these tests were called significant,
over the long-term, a minimum false discovery rate of ∼28% would be incurred). As the pre-
specified q-value threshold was 0.10, no SNP reached genomewide significance. The
proportion of all SNPs without true effects (p0) (54) was conservatively estimated to be
p0=0.9999954, consistent with the presence of ∼2 SNPs with true effects in these GWAS
data. The results of this MDD GWAS are included as a Supplemental File (“results.txt”) to
facilitate comparisons with other studies.
Panel a of Figure 1 depicts the quantile-quantile plots (40) for these analyses. The observed
p-values do not strongly depart from the p-value distribution expected by chance. Panel b of
Figure 1 shows a plot of –log10(ptrend) by genomic location.
Table 2 presents the findings for the top 25 SNPs. The quality control metrics – SNP
missingness, agreement with HWE, and similarity of the control MAFs to the HapMap EUR
panel – for the top 25 SNPs are generally acceptable. Four of the top 25 associations are in
the presynaptic cytomatrix protein piccolo (PCLO). Table 3 depicts the top 25 multi-SNP
clusters (i.e., for an index SNP with association p<0.001, these clusters are additional SNPs
within 250 kb of the index SNP with with r2 ≥ 0.50). The full version of this table is
included as a Supplemental File (“Table3_full.xls”). PCLO is present in the top 25 clusters
along with two additional multi-SNP clusters in the top 200. Other notable SNP clusters
occurred in GRM7 (rank 51), DGKH (rank 83, a candidate gene for bipolar disorder) (70),
DAOA (rank 124), and DRD2 (rank 226).
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Focusing on Piccolo (PCLO)
Although no association met genomewide significance, there were clusters of SNPs in
PCLO (Figure 2). Notably, 11 of the 200 smallest p-values localized to a 167 kb segment
overlapping PCLO. Interest in PCLO was increased given its expression in brain,
localization to the presynaptic active zone (71), and involvement in monoamine
neurotransmission, a venerable hypothesis of the etiology of MDD (72). Moreover, the third
most significant SNP (rs2522833) codes for a non-synonymous amino acid change
(ala-4814-ser) in PCLO near its C2A calcium binding domain (73).
We investigated possible causes of spurious associations in the PCLO region
(chr7:82,032,093-82,436,848). First, these findings were not due to plate effects as
inspection of plate-specific association data for these SNPs did not show any marked
outliers or systematic biases. Second, review of allelic intensity cluster plots on which
genotype calls were based revealed adequate performance of the Perlegen genotype calling
algorithm. Third, inspection of additional quality control metrics did not suggest systematic
problems with SNPs in this region. Fourth, inspection of LD matrices excluded very high
LD as the sole explanation for the results (Supplemental Figure 10), and none of the
genotyped SNPs had strong LD (r2 ≥ 0.8) with rs2715148 (the SNP with the smallest p-
value in the PCLO region). Fifth, population stratification can cause false positive findings
but this did not appear to explain the PCLO association: (a) the same 11 SNPs had p-values
among the top 200 associations in unadjusted analyses as well as with adjustment via
principal components and stratified analyses; and (b) for the 57 SNPs in the PCLO region,
the p-values across these three types of analyses were consistent (the Spearman correlations
between p-values from trend tests, logistic regression, and stratified analyses were all
>0.962). Sixth, the minor allele frequencies in the control group in the PCLO region were
usually quite similar to available EUR control groups suggesting that the PCLO findings
were not due to an artifact of the control selection process (see below). Finally,
bioinformatic investigation did not suggest that this is a problematic region to genotype as
the PCLO region is not known to be under positive selection in humans (74), to contain
segmental duplications (67), or common copy number variants (search of the Database of
Genomic Variants yielded two rare CNVs with control frequencies of 0.12% and 0.89%)
(75, 76 , 77).
We conducted additional analyses to attempt to localize the association depicted in Figure 2.
Imputation (56) supported the directly typed SNP associations but did not yield an
association p-value markedly more significant than any directly genotyped SNP (although
22 of the 25 most significant imputed associations in the genome were in this region).
Haplotype analysis using 3-SNP sliding windows did not improve localization. Secondary
analyses by sex, case ascertainment setting, and recurrent early-onset MDD (reoMDD,
arguably the most heritable form of MDD) (16,78) suggested that most of the signal was
from females and from subjects with reoMDD (Supplemental Table 11). The findings for
reoMDD were often stronger than the primary analyses, particularly for the most significant
SNP (rs2715148) where the p-value decreased by 1.2 orders of magnitude to 9.5×10−8.
PCLO Replication
Although no finding met genomewide significance, the presence of multiple possible signals
in PCLO and the plausibility of a role for PCLO in the etiology of MDD led us to attempt
replication in external samples. We assembled a collection of 11,972 independent subjects
(6,079 MDD cases and 5,893 controls) from seven different groups and a total of six case-
control replication samples (two German samples were combined, see Supplemental
Methods). As with NESDA cases, all replication cases were adults of European ancestry on
whom a structured clinical interview was used to substantiate the lifetime diagnosis of
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DSM-IV MDD (1), and all studies excluded common MDD phenocopies (e.g., depressive
symptoms due to another psychiatric disorder or a general medical condition). As with NTR
controls, all replication controls were adults of European ancestry ascertained from the
population, and individuals reporting MDD symptoms were excluded. We estimated
statistical power using Quanto (57) (assumptions: log-additive genetic model, MDD lifetime
risk 0.15, MAF=0.45 (similar to rs2522833), a genotypic relative risk of 1.14 (“shrunk”
down from the observed GRR of 1.26 for rs2522833 to account for the “Winner's Curse”
phenomenon) (79), and a conservative two-tailed type 1 error rate of 0.00167 (=0.05/30
replication SNPs). Statistical power was 97.2% for replication for the two SNPs genotyped
in all samples (N=11,972) and 90.4% for the remaining SNPs (N=9,278). Five replication
samples were genotyped for 30 SNPs using the same Sequenom iPlex SNP pool (15 SNPs
were in the primary GWAS and 15 were selected to tag common variation in Europeans)
(80) and one sample was successfully genotyped for two SNPs using TaqMan. The SNP
selection strategy effectively cast a broad net over the region showing association in Figure
2. For the NESDA/NTR samples, agreement between the initial Perlegen genotypes in this
region and independent re-genotyping was high (0.9987).
The single SNP results for MDD are depicted in Figure 3 and Table 4a. Our analytic plan
dictated the combined analysis of all replication samples with the use of a one-tailed
directional test. No association in the replication sample reached statistical significance after
correction for multiple comparisons and SNP non-independence due to LD (ninth column in
Table 4a). Similarly, haplotype analyses did not reveal significantly associated regions
(Supplemental Figure 16). There were four p-values <0.05 in the replication sample but only
rs10954694 also had Z-scores of the same sign in both samples. Table 4b shows the results
for reoMDD, and no single SNP was significant after correction for multiple comparisons.
When we repeated the MDD analyses restricted to female subjects, the observed
significance levels did not become markedly stronger in any of the replication samples in
contrast to the initial NESDA/NTR sample. Thus, results from analyses of all replication
samples did not reach the a priori criterion for replication evidence for the involvement of
PCLO in the etiology of MDD.
Unanticipated heterogeneity in cases
However, we observed, a posteriori, that there was potentially important heterogeneity in the
replication samples for eight SNPs that were strongly associated in the original sample
(I2≥0.4, ninth column in Table 4a). In investigating this further (Supplemental Methods), we
determined that there was little evidence for genetic heterogeneity in the genotyped region
for controls but, unexpectedly, there was significant heterogeneity in the cases. Principal
components analysis and inspection of Table 4a and the forest plots in Figure 3 indicated
that the outlier was the Australian QIMR sample. Notably, the original and QIMR samples
were particularly similar in that both studies included population-based cases and controls
were selected to be at low liability for MDD based on longitudinal assessments. Of the nine
SNPs with p<0.05 in the QIMR sample, eight had both low p-values and Z-scores with the
same sign as in the NESDA/NTR sample. As an exploratory analysis, we analyzed the
original and QIMR samples jointly, and the minimum p-value was 6.4×10−8 at the non-
synonymous SNP rs2522833 that gives rise to a serine to alanine substitution near the C2A
calcium-binding-domain of the PCLO protein.
Secondary analyses
We conducted additional analyses of the NESDA/NTR GWAS dataset that were specified a
priori but which should be considered exploratory.
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(a) The network of proteins with which PCLO interacts in its role at the presynaptic
cytoskeletal matrix is relatively well-characterized, and we reasoned that genes encoding
these proteins might harbor risk or protective variants. We assessed this hypothesis by
testing for association conditioning on the PCLO nsSNP rs2522833 (i.e., investigating
whether controlling statistically for the effect of rs2522833 increases the salience of other
SNP associations), assessing the minimum p-value per gene, and then comparing this list to
a list of 54 genes that make proteins that interact with PCLO. This analysis did not reveal
any SNPs or genes whose significance was markedly lower than without including
rs2522833 in the logistic regression model. Moreover, no known PCLO interacting protein
was notable on this list.
(b) We imputed genotypes for 2,037,829 autosomal SNPs using MACH with reference to
HapMap CEU genotypes. The resulting lambda was 1.048, and the minimum p-value was
1.21×10−7. As noted above, 22 of the 25 most significant imputed associations were in the
PCLO region. Investigation of SNP clustering that accounted for LD yielded results similar
to those shown in Table 3.
(c) We assembled a list of 103 candidate genes that had been studied for association with
MDD in the literature (81). Nineteen of these genes had no SNPs within its transcript and
another 9 genes had inadequate coverage (>1 SNP/15 kb; Supplemental Table 17). Of the
remaining 75 genes, only NOS1 (neuronal nitric oxide synthase, p=0.0006) had p<0.001.
However, NOS1 (as with most genes in Supplemental Table 16) is quite large and chance is
a prominent potential influence on these results.
(d) We compared the GWAS association results to a meta-analysis of gene expression data
from 12 studies of post-mortem brain tissue in MDD cases compared with controls (10
frontal cortex and 2 cerebellum studies). These data are available via the Stanley Foundation
(http://www.stanleygenomic.org). There were five genes with GWAS p<0.05 (all had gene
expression changes significant at p 0.0004 – 0.007). The genes were: SGCG (sarcoglycan),
CALD1 (caldesmon 1), EEF1A1 (eukaryotic translation elongation factor 1 alpha 1),
CFLAR (CASP8 and FADD-like apoptosis regulator), and TP73L (tumor protein p73-like).
There is no overlap of this list with the PCLO interactors or MDD candidate genes from the
literature.
(d) Alternative models, filters, and phenotypes. (i) For reoMDD, the minimum p-value over
all GWAS SNPs was at the PCLO region SNP rs2715148 (8.4×10−8) which ranked second
of all SNPs using the trend test (Table 2). (ii) rs2715148 also had the smallest p-value under
a dominant model of SNP action (6.2×10−6). (iii) Given the female predominance in MDD,
we analyzed data from females and males separately. For female cases and controls,
rs2715148 had the smallest p-value (4.0×10−7) and multiple other PCLO SNPs had p-values
in the 10−5 – 10−6 range. For males, most PCLO SNPs had p > 0.05 and the minimum was
in the SLC9A9 SNP rs4839627 (9.1×10−7). (iv) Again, given sex differences in MDD
prevalence, we investigated SNPs on chrX and chrY more closely. The minimum p-value in
chrX pseudo-autosomal region 1 was 0.02. For the non-PAR regions of chrX in females, the
SNPs with the smallest p-values were rs11094388 (p=0.0003, intergenic), rs5971108
(p=0.0003, PTCHD1), rs5930667 (p=0.0004, intergenic), rs4618863 (p=0.0005, intergenic),
rs2207796 (p=0.0005, in the very large gene DMD), and rs5936428 (p=0.0009, FMR2). For
males, the minimum p-value on chrX was at rs10521594 (p=5.4×10−5, intergenic) and 0.22
on chrY.
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Discussion
Overview
Major depressive disorder (MDD) is a common complex trait of enormous public health
significance. As part of the GAIN initiative of the US Foundation for the NIH (19), we
conducted a genomewide association study of 435,291 SNPs genotyped in 1,738 MDD
cases and 1,802 controls selected to be at low liability for MDD. Our study had numerous
positive attributes including its historically large sample size, its largely population-based
and longitudinal design, and relatively unbiased and dense genomewide genotyping
designed to capture common variation in subjects of European ancestry.
According to our primary analysis plan, no SNP-MDD phenotype association reached
genomewide significance as the minimum q-value was 0.28, greater than the pre-defined q-
value threshold of 0.10. This result was not unexpected. For example, type 2 diabetes
mellitus has arguably reaped the greatest harvest from GWAS (82) and yet two of the initial
T2DM GWAS were unremarkable when analyzed independently (83,84). One of the key
lessons of the GWAS era is the importance of meta-analysis where its application to the
primary GWAS can uncover positive findings that replicate well across studies (18,85).
Is PCLO a causal risk factor for MDD?
Although no locus exceeded the genomewide threshold after correction for multiple
comparisons, 11 of the top 200 signals localized to a 167 kb region overlapping the gene
piccolo (PCLO). The protein product of PCLO localizes to the presynaptic active zone and
plays an important role in brain monoaminergic neurotransmission (86), clearly intersecting
with a venerable hypothesis of the etiology of mood disorders (87). Moreover, the third most
significant association was a common non-synonymous SNP near its critical C2A binding
domain in PCLO (88,89). Although it is an obvious candidate gene, we are not aware of any
prior association studies of PCLO and mood disorders (PCLO is in a region of 7q implicated
by linkage in autism and one autism association study has been published) (90).
We judged the intersection of this GWAS result with prior knowledge sufficient to trigger a
large-scale replication effort by genotyping PCLO SNPs in 6,079 MDD independent cases
and 5,893 controls. Statistical power to replicate exceeded 90% even after accounting for
(79) the “Winner's Curse” phenomenon (a form of regression to the mean whereby the true
genotypic relative risk is over-estimated in the initial study) (91,92). However, in spite of the
apparent a priori strength of a hypothesis of genetic variation in PCLO in the etiology of
MDD, no SNP analyzed in the replication sample met appropriately rigorous criteria for
replication (21). Therefore, unlike GWAS for many non-psychiatric biomedical disorders,
our GWAS and replication efforts did not yield “proof beyond a reasonable doubt” level of
evidence for an association between genetic variation in PCLO and MDD.
Investigation of the sources of heterogeneity in the replication samples indicated that
controls were genetically similar to the original sample in the PCLO region but that cases
were dissimilar. We observed, a posteriori, that both principal components derived from
PCLO region genotypes in QIMR cases and effect size estimates in the QIMR replication
sample tended to be similar to the original sample. This is notable because, of all the
replication samples, ascertainment of QIMR subjects was most similar to the primary
NESDA/NTR sample in that cases were identified from population-based sources (100% for
QIMR and 60% for NESDA) rather than tertiary sources as for the other replication samples.
MDD cases from clinical samples may differ from population-based cases due to selection
bias (93), Berkson's bias (94,95), differing referral filters (96), or even a different genetic
basis (97) with respect to genetic variation in the PCLO region.
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Joint analysis of the NESDA/NTR and QIMR samples yielded p=6.4x10-8 (uncorrected for
multiple hypothesis testing) for the non-synonymous SNP rs2522833. This result suggests a
specific hypothesis for future studies: an association between genetic variation in PCLO and
MDD may be detected only in population-based cases. Thus, it would be premature to
exclude PCLO from a role in the etiology of some forms of MDD.
The Heterogeneous Nature of MDD
Interpretation of the PCLO replication efforts is consistent with two broad possibilities. The
first possibility is that genetic variation in PCLO is truly not associated with MDD. This
interpretation is supported by the replication analyses (specified a priori) in which no SNP
was significantly associated after correction for multiple comparisons and SNP dependence
due to LD. This strict interpretation is generally viewed as “best practice” in human genetics
(21) but implicitly assumes etiological homogeneity for MDD in the PCLO region. The
second possibility invokes a less parsimonious model involving heterogeneity, that genetic
variation in PCLO is etiologically causal to some subtypes of MDD. This interpretation is an
a posteriori hypothesis consistent with the empirical results particularly in the notable
differences in associations between samples, case ascertainment strategies, and indications
from principal components analysis that NESDA and QIMR cases are more similar than the
clinically ascertained subjects. It is notable that the control samples from each site were
considerably more similar than cases from the same sites.
The tension between null a priori results and plausible a posteriori hypotheses is a core issue
in psychiatric genetics. Important phenotypes like MDD are defined reliably and with
reference to diagnostic schema developed principally for clinical purposes. Heterogeneous
etiology of MDD is widely suspected but there are no proven ways to index heterogeneity
(indeed, a prominent rationale for genetics studies is improve differential diagnosis).
Our results are consistent with prior observations of the heterogeneous nature of MDD,
particularly with regard to ascertainment. Individuals who meet MDD criteria from
community or primary care sources may have a more inclusive and less comorbid form of
MDD (98) whereas tertiary ascertainment may yield subjects with greater comorbidity and
perhaps distinctive etiology (99). In particular, it is formally possible (but unproven) that the
PCLO results are accurate – genetic variation in PCLO might be causal to the types of MDD
seen in community samples but other loci contribute to a distinctive type of MDD seen in
tertiary care samples.
Other hypotheses
There were two MDD cases who may have had unrecognized genomic disorders (100)
(possible Turner's and Klinefelter's syndromes). We speculate that small numbers of cases
with MDD will have CNV-related genomic disorders that are plausibly causal to MDD.
Clarification of the role of such rare variants will require larger samples.
Most of the additional exploratory analyses were unrevealing, including examination of
proteins known to interact with PCLO, genotype imputation, comparison of GWAS findings
with MDD candidate genes from the literature and gene expression changes in the brain in
cases with MDD, and alternative genetic models, phenotype definitions, and sex-specific
analyses.
We searched the SLEP compendium of psychiatric genetics findings (101) to attempt to
discover overlap of our findings with those reported in the literature. First, with reference to
a meta-analysis of microarray studies on the Stanley brain bank MDD and control samples,
expression of CFLAR and MARCH3 were increased and LST1 and HLA-B were decreased
in MDD post-mortem frontal cortex. These regions ranked 9, 232, 267, and 432 in the
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NESDA/NTR GWAS. Second, we looked for convergence of our findings with other
GWAS of psychiatric disorders. Notable genomic locations of overlap of the top 480 regions
in the present GWAS were found with GWAS for ADHD (ITIH1, S Faraone, personal
communication), the WTCCC GWAS for bipolar disorder (SHFM1 and UGT2B4) (102),
and a bipolar GWAS that used DNA pooling (GRM7 and DGKH) (70). Third, we looked at
the minimum p-values in our study for genes that met or nearly achieved genomewide
significance: the minimum p-values in our study for MAMDC1 (103) was 0.004, 0.03 for
ZNF804A (104), 0.002 in ANK3 (105), and 0.03 in CACNA1C (105). These overlaps are
intriguing (although the play of chance cannot be excluded), and will be formally
investigated as part of our participation in the Psychiatric GWAS Consortium analyses (18).
Limitations
(a) Although statistical power has been systematically underestimated in psychiatric
genetics, when we began this study in Q3 2006, it was believed that statistical power would
be reasonable to detect realistic genetic effects. However, the definition of “realistic” has
shifted considerably since 2006 and it may be important to design studies that can detect
genotypic relative risks <1.10. (b) When this study began, the coverage and performance of
the Perlegen GWAS platform were among the better options available (19). The technology
and pricing have evolved rapidly and superior platforms are now available. A key limitation
of the Perlegen platform is its inability to assess copy number variation (106) that may be
particularly salient for psychiatric disorders (107,108). More generally, the GWAS platform
might not be sufficiently “genomewide” and unbiased: the platform may have had
inadequate coverage in an etiologically important region of the genome, SNPs are only one
type of genetic variation, and important non-SNP genetic variation might not have been
sufficiently well captured. (c) There was an imbalance in the proportion of males in cases
and controls. Although it is unclear whether and how this might bias the results, it may have
lead to some degree of bias. (d) Finally, GWAS are predicated upon the crucial assumption
that the predominant diagnostic criteria are valid with respect to the fundamental
architecture of the disorder.
Conclusions
We describe here a large effort to identify DNA sequence variation fundamental to MDD.
Although our initial GWAS results for the PCLO region were intriguing, this highly
plausible hypothesis did not find support in a large-scale replication attempt. Our hypothesis
about a role of genetic variation in PCLO for MDD in population but not clinical settings
emphasizes the importance of knowing the epidemiological sampling frame for a study.
Finally, we hope that the model we used in this study – a cooperative international effort –
will be adopted by groups studying other psychiatric disorders in order to maximize
progress.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
GWAS results for MDD in cases versus controls. Panel a shows the quantile-quantile plots
and lambda estimates for the primary analysis using the Cochran-Armitage trend test and
confirmatory analyses using logistic regressions and Cochran-Mantel-Haenszel stratified
tests. The dashed lines show the expected 95% probability interval for ordered p-values, and
the circles show the observed versus expected values for all SNPs. The λ values are the
median Χ2 from all association tests divided by the expected value under the null hypothesis
of no association. If λ is large (e.g., >1.2), there is evidence that the observed test statistics
deviate from the expected. This could be due to true associations but is more likely due to a
systematic bias (e.g., population stratification effects). The λ values in Panel a are not
consistent with the presence of stematic biases in the results. Panel b depicts −log10(p) by
genomic location for chr1-chr22 plus chrX. Odd-numbered chromosomes are in light blue
and even-numbered chromosomes in orange. The 25 smallest p-values are shown with green
crosses.
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Figure 2.
Plot of the PCLO region (NCBI build 35, UCSC hg17, chr7:82,000,000-82,500,000). P-
values in this figure are all from SNPMstat. The x-axis is chromosomal position, the left y-
axis −log10(p) for genotyped SNPs (colored diamonds) and imputed SNPs (grey diamonds),
and the right y-axis the recombination rate from the HapMap EUR panel (light blue curve).
The color of the genotyped SNPs corresponds to LD with the SNP with smallest p-value
(rs2715148): red 0.8 ≤ r2 ≤ 1.0, orange 0.5 ≤ r2 < 0.8, yellow 0.2 ≤ r2 < 0.5, and white r2 <
0.2. The significant and extent of all 3-SNP haplotypes with p<0.0001 in this region are
colored light green. The transcripts for two PCLO isoforms are shown in dark green at the
bottom. Graph adapted from an R function by the Broad DGI group.
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Figure 3.
PCLO region replication results for MDD showing genomic context and forest plots for the
top 12 SNPs in the original sample. The backbone of the graph is the region of PCLO
targeted for follow-up. SNP locations are given by the grey triangles. There are 12 forest
plots for the SNPs with p<0.001 in the original sample. Each forest plot is for one SNP and
shows the odds ratio (square) and 95% confidence intervals (horizontal line) for a particular
sample with the area of the square proportional to sample size.
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Table 1
Descriptive data for cases with MDD and controls at low liability for MDD included in the GWAS.
Descriptor Cases Controls Test
Number of subjects genotyped 1,738 1,802 -
Mean age in years (SD) 42.6 (12.6) 45.1 (14.1) F1,3538=31.1, p<0.001
Female, % 69.6 62.0 χ12 = 22.5, p<0.001
Educational level (% low/middle/high) 7.8 / 62.0 / 32.2 5.7 / 56.3 / 38.1 χ22 = 16.3, p<0.001
Partner status, % with partner 68.9 87.0 χ12 = 167.2, p<0.001
Smoking (current), % 42.0 20.2 χ12 = 194.5, p<0.001
Mean neuroticism (NEO, SD) 39.3 (8.0) 28.2 (5.5) F1,2920=1831, p<0.001
MDD, age of onset in years (SD)
Early age of onset (< 30 years), %
27.7 (12.4)
57.3 -
Family history of depression, % 85.5 -
Recurrent MDD 50.9 -
Family history, recurrent MDD, or early
age of onset (< 30 years) 94.8 -
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Table 4
PCLO replication results.
Abbreviations: N=total sample size for an analysis, Z=logistic regression beta divided by its standard error, P=asymptotic p-value from Wald chi-
square test (1 df) uncorrected for multiple comparisons, P_corr=empirical p-value from accounting for multiple comparisons and LD structure
(50K permutations), and I^2=i-squared, an index of heterogeneity of logistic regression parameter estimates.
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